Stage IV Renal Cell Cancer AJCC v8 Clinical Trial
Official title:
A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)
Verified date | June 2024 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | July 1, 2027 |
Est. primary completion date | July 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants must have a histologically confirmed diagnosis of metastatic papillary renal cell carcinoma (PRCC), either type 1 or type 2. (NOTE: A designation of type 1 or type 2 should be made by the local pathologist if possible but is not required). Mixed histologies which contain type 1 or type 2 along with any other RCC histology/histologies will be allowed provided that they contain a papillary component - Participants must have measurable disease per RECIST 1.1 criteria. All measurable lesions must be assessed by CT or magnetic resonance imaging (MRI) within 28 days prior to registration. All non-measurable lesions must be assessed by CT or MRI, or nuclear medicine bone scan within 42 days prior to registration. The CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality. If there is clinical suspicion for bone metastases at the time of enrollment (at the discretion of the investigator), bone scan must be performed at baseline (within 42 days prior to registration) - Participants with new or progressive brain metastases (active brain metastases) must not require immediate central nervous system (CNS) specific treatment at the time of study registration or anticipated during the first cycle of therapy. Patients with leptomeningeal disease are excluded from enrolling - Participants with measurable disease, per RECIST version (v)1.1, must be present outside the CNS - Participants must have no history of intracranial hemorrhage or spinal cord hemorrhage - Participants, if needed, must receive a stable dose of anti-convulsant therapy - Participants must complete all prior radiation therapy at least 14 days prior to registration. Participants must have recovered to =< grade 1 from all associated toxicities at the time of registration unless the toxicity is determined to be not clinically significant by the registering investigator - Participants must be >= 18 years of age - Participants must have a complete physical examination and medical history within 28 days prior to registration - Participants must have a Zubrod performance status of 0-2 - White blood count (WBC) >= 2 x 10^3/uL (within 28 days prior to registration) - Absolute neutrophil count (ANC) >= 1.5 x 10^3/uL (within 28 days prior to registration) - Platelet count >= 100 x 10^3/uL (within 28 days prior to registration) - Lymphocyte count >= 0.5 x 10^3/uL (within 28 days prior to registration) - Hemoglobin (>= 9 g/dL) (within 28 days prior to registration). Participants may be transfused to meet this criterion - Total serum bilirubin =< 1.5 x the institutional upper limit of normal (ULN) unless history of Gilbert's disease (within 28 days prior to registration). Participants with history of Gilbert's disease must have total bilirubin =< 5 x institutional ULN - Aspartate aminotransferase (AST) must be =< 3 x the institutional ULN unless the liver is involved with the tumor, in which case serum transaminase (SGOT) must be =< 5 x the institutional ULN (within 28 days prior to registration) - Alanine aminotransferase (ALT), must be =< 3 x the institutional ULN unless the liver is involved with the tumor, in which case serum transaminase (SGPT) must be =< 5 x the institutional ULN (within 28 days prior to registration) - Participants must have serum creatinine =< 2 x the institutional ULN OR creatinine clearance (either measured or calculated) > 30 mL/min and obtained within 28 days prior to registration - Participants must have urine protein < 3+ within 28 days prior to registration. If urine protein is 3+ or greater, then urine protein by 24-hour collection must show less than 3 grams of protein - Participants must have documented blood pressure of systolic blood pressure (SBP) < 150 mm Hg or diastolic blood pressure (DBP) < 100 mm Hg within 14 days prior to registration - Participants with known human immunodeficiency virus (HIV) must be on effective anti-retroviral therapy at registration and have undetectable viral load within 6 months of registration - Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy within 6 months prior to registration, if indicated - Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load within 6 months prior to registration - Participants must be able to take oral medications (i.e., swallow pills whole). Participants must not have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures that could in the opinion of the treating investigator affect absorption, or active peptic ulcer disease. Participants with intractable nausea or vomiting are not eligible - Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System - Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines - NOTE: For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations - As a part of the OPEN registration process for OPEN access instructions) the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system Exclusion Criteria: - Participants must not have undergone stereotactic radiotherapy within 7 days prior to initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, or neurosurgical resection within 28 days prior to initiation of study treatment - Participants must not have ongoing requirements for corticosteroids as therapy for CNS disease - Participants must not have cavitating pulmonary lesions - Participants must not have uncontrolled pleural effusions, pericardial effusions, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Participants with indwelling catheters (e.g., PleurX) are allowed - Participants must not have tumor invading the gastrointestinal (GI) tract or evidence of endotracheal or endobronchial tumor within 28 days prior to registration - Participants must not have evidence of tumor invading or encasing any major blood vessels - Participants must not have had major surgery within 28 days prior to registration, and participants must have recovered from any adverse effects of surgery - Participants must not have had prior treatment with cabozantinib for any reason - Participants must not have had prior treatment or adjuvant therapy with PD-1/PD-L1 checkpoint inhibitors for any reason within the past 6 months - Participants must not have received more than one prior systemic therapy for advanced or metastatic renal cell carcinoma with the exception of another VEGF inhibitor Food and Drug Administration (FDA)-approved for advanced RCC (i.e., pazopanib, bevacizumab, sorafenib or axitinib). If a participant develops metastatic disease within six months of discontinuation of adjuvant therapy, this will constitute one prior systemic therapy for advanced or metastatic RCC. If a patient develops metastatic disease and more than six months has elapsed since discontinuation of adjuvant therapy, this will not constitute prior systemic therapy for advanced or metastatic RCC - Participants must not take within 14 days prior to registration, nor plan to take while on protocol treatment, any strong CYP3A4 inhibitors (e.g. boceprevir, cobicistat, danoprevir, elvitegravir/RIT, fluvoxamine, indinavir, itraconazole, ketoconazole, lopinavir/RIT, nefazodone, nelfinavir, posaconazole, ritonavir, telaprevir, telithromycin, tipranavir/RIT, or voriconazole,); Please refer to https://drug-interactions.medicine.iu.edu/MainTable.aspx for the updated CYP3A4 inhibitors or inducers - Participants must not take within 14 days prior to registration, nor plan to take while on protocol treatment, any strong CYP3A4 inducers (e.g. avasimibe, phenytoin, rifampin, rifabutin); Please refer to https://drug-interactions.medicine.iu.edu/MainTable.aspx for the updated CYP3A4 inhibitors or inducers - Participants must not be receiving or planning to receive any other investigational agents at time of registration - Participants must not have been diagnosed with a clinically significant autoimmune disease, exceptions such as diabetes, eczema, and vitiligo are allowed. Other non-clinically significant autoimmune diseases are allowed if approved by the registering investigator - Participants must not be on steroid doses > 10 mg prednisone equivalent. Replacement steroid doses for adrenal insufficiency will be allowed. Also, short duration steroid therapy to prevent allergic reactions are acceptable (e.g. prior to CT imaging) - Participants must not have any clinical evidence of congestive heart failure (CHF) (specifically, New York Heart Association [NYHA] class III [moderate] or class IV [severe]) at the time of registration - Participants must not have known history of congenital long QT syndrome and must not have experienced unstable angina pectoris, clinically significant cardiac arrhythmias, or stroke (transient ischemic attack [TIA] or other ischemic event) within 90 days prior to registration - Participants must not have experienced myocardial infarction or thromboembolic event requiring anticoagulation within 90 days of registration, unless clinically stable with ongoing medical management - Participants must not have had any clinically-significant GI bleeding within 3 months prior to registration and participants must not have a GI disorder which (at the discretion of the investigator) bears a high risk of perforation or fistula (e.g. Crohn's disease) - Participants must not have had hemoptysis of >= (2.5 mL) of red blood, and do not demonstrate any other signs indicative of pulmonary hemorrhage within 3 months prior registration - Participants must not be pregnant or nursing, due to VEGF therapy being toxic to embryogenesis. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen - Participants must not be on warfarin, at therapeutic doses. Low dose aspirin for cardio-protection (per local applicable guidelines) and low molecular weight heparin (LMWH) are allowed |
Country | Name | City | State |
---|---|---|---|
United States | Mary Greeley Medical Center | Ames | Iowa |
United States | McFarland Clinic - Ames | Ames | Iowa |
United States | Kaiser Permanente-Anaheim | Anaheim | California |
United States | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor | Michigan |
United States | UH Seidman Cancer Center at UH Avon Health Center | Avon | Ohio |
United States | Kaiser Permanente-Baldwin Park | Baldwin Park | California |
United States | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland |
United States | Bronson Battle Creek | Battle Creek | Michigan |
United States | UHHS-Chagrin Highlands Medical Center | Beachwood | Ohio |
United States | Kaiser Permanente-Bellflower | Bellflower | California |
United States | Illinois CancerCare-Bloomington | Bloomington | Illinois |
United States | Saint Luke's Cancer Institute - Boise | Boise | Idaho |
United States | McFarland Clinic - Boone | Boone | Iowa |
United States | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Michigan |
United States | Trinity Health Medical Center - Brighton | Brighton | Michigan |
United States | Illinois CancerCare-Canton | Canton | Illinois |
United States | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Michigan |
United States | Trinity Health Medical Center - Canton | Canton | Michigan |
United States | Saint Francis Medical Center | Cape Girardeau | Missouri |
United States | Caro Cancer Center | Caro | Michigan |
United States | Illinois CancerCare-Carthage | Carthage | Illinois |
United States | Duke Cancer Institute Cary | Cary | North Carolina |
United States | Miami Valley Hospital South | Centerville | Ohio |
United States | Chelsea Hospital | Chelsea | Michigan |
United States | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Michigan |
United States | Northwestern University | Chicago | Illinois |
United States | Case Western Reserve University | Cleveland | Ohio |
United States | Southeastern Medical Oncology Center-Clinton | Clinton | North Carolina |
United States | Mercy Hospital | Coon Rapids | Minnesota |
United States | UT Southwestern Simmons Cancer Center - RedBird | Dallas | Texas |
United States | UT Southwestern/Simmons Cancer Center-Dallas | Dallas | Texas |
United States | Carle at The Riverfront | Danville | Illinois |
United States | Dayton Physician LLC - Englewood | Dayton | Ohio |
United States | Miami Valley Hospital | Dayton | Ohio |
United States | Miami Valley Hospital North | Dayton | Ohio |
United States | Premier Blood and Cancer Center | Dayton | Ohio |
United States | Cancer Care Specialists of Illinois - Decatur | Decatur | Illinois |
United States | Decatur Memorial Hospital | Decatur | Illinois |
United States | Northwestern Medicine Cancer Center Kishwaukee | DeKalb | Illinois |
United States | Mercy Medical Center - Des Moines | Des Moines | Iowa |
United States | Wayne State University/Karmanos Cancer Institute | Detroit | Michigan |
United States | Illinois CancerCare-Dixon | Dixon | Illinois |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | Epic Care-Dublin | Dublin | California |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Marshfield Medical Center-EC Cancer Center | Eau Claire | Wisconsin |
United States | Fairview Southdale Hospital | Edina | Minnesota |
United States | Carle Physician Group-Effingham | Effingham | Illinois |
United States | Crossroads Cancer Center | Effingham | Illinois |
United States | Epic Care Partners in Cancer Care | Emeryville | California |
United States | Illinois CancerCare-Eureka | Eureka | Illinois |
United States | Farmington Health Center | Farmington | Utah |
United States | Parkland Health Center - Farmington | Farmington | Missouri |
United States | Weisberg Cancer Treatment Center | Farmington Hills | Michigan |
United States | Genesee Cancer and Blood Disease Treatment Center | Flint | Michigan |
United States | Genesee Hematology Oncology PC | Flint | Michigan |
United States | Genesys Hurley Cancer Institute | Flint | Michigan |
United States | Hurley Medical Center | Flint | Michigan |
United States | Kaiser Permanente-Fontana | Fontana | California |
United States | McFarland Clinic - Trinity Cancer Center | Fort Dodge | Iowa |
United States | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth | Texas |
United States | Atrium Medical Center-Middletown Regional Hospital | Franklin | Ohio |
United States | Saint Luke's Cancer Institute - Fruitland | Fruitland | Idaho |
United States | Illinois CancerCare-Galesburg | Galesburg | Illinois |
United States | Northwestern Medicine Cancer Center Delnor | Geneva | Illinois |
United States | Northwestern Medicine Glenview Outpatient Center | Glenview | Illinois |
United States | Southeastern Medical Oncology Center-Goldsboro | Goldsboro | North Carolina |
United States | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids | Michigan |
United States | Northwestern Medicine Grayslake Outpatient Center | Grayslake | Illinois |
United States | Miami Valley Cancer Care and Infusion | Greenville | Ohio |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Kaiser Permanente - Harbor City | Harbor City | California |
United States | Kaiser Permanente-Irvine | Irvine | California |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Southeastern Medical Oncology Center-Jacksonville | Jacksonville | North Carolina |
United States | McFarland Clinic - Jefferson | Jefferson | Iowa |
United States | Ascension Borgess Cancer Center | Kalamazoo | Michigan |
United States | Bronson Methodist Hospital | Kalamazoo | Michigan |
United States | West Michigan Cancer Center | Kalamazoo | Michigan |
United States | Kettering Medical Center | Kettering | Ohio |
United States | Illinois CancerCare-Kewanee Clinic | Kewanee | Illinois |
United States | Northwestern Medicine Lake Forest Hospital | Lake Forest | Illinois |
United States | University of Michigan Health - Sparrow Lansing | Lansing | Michigan |
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
United States | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia | Michigan |
United States | Kaiser Permanente Los Angeles Medical Center | Los Angeles | California |
United States | Kaiser Permanente West Los Angeles | Los Angeles | California |
United States | Illinois CancerCare-Macomb | Macomb | Illinois |
United States | Saint John's Hospital - Healtheast | Maplewood | Minnesota |
United States | Saint Mary's Oncology/Hematology Associates of Marlette | Marlette | Michigan |
United States | McFarland Clinic - Marshalltown | Marshalltown | Iowa |
United States | Marshfield Medical Center-Marshfield | Marshfield | Wisconsin |
United States | Contra Costa Regional Medical Center | Martinez | California |
United States | Carle Physician Group-Mattoon/Charleston | Mattoon | Illinois |
United States | Loyola University Medical Center | Maywood | Illinois |
United States | Saint Luke's Cancer Institute - Meridian | Meridian | Idaho |
United States | East Jefferson General Hospital | Metairie | Louisiana |
United States | LSU Healthcare Network / Metairie Multi-Specialty Clinic | Metairie | Louisiana |
United States | Abbott-Northwestern Hospital | Minneapolis | Minnesota |
United States | Marshfield Clinic-Minocqua Center | Minocqua | Wisconsin |
United States | Trinity Health Muskegon Hospital | Muskegon | Michigan |
United States | Saint Luke's Cancer Institute - Nampa | Nampa | Idaho |
United States | Touro Infirmary | New Orleans | Louisiana |
United States | University Medical Center New Orleans | New Orleans | Louisiana |
United States | Providence Newberg Medical Center | Newberg | Oregon |
United States | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores | Michigan |
United States | Cancer Care Center of O'Fallon | O'Fallon | Illinois |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | Kaiser Permanente-Ontario | Ontario | California |
United States | Providence Willamette Falls Medical Center | Oregon City | Oregon |
United States | Northwestern Medicine Orland Park | Orland Park | Illinois |
United States | Illinois CancerCare-Ottawa Clinic | Ottawa | Illinois |
United States | Kaiser Permanente - Panorama City | Panorama City | California |
United States | Illinois CancerCare-Pekin | Pekin | Illinois |
United States | Illinois CancerCare-Peoria | Peoria | Illinois |
United States | Illinois CancerCare-Peru | Peru | Illinois |
United States | Cancer Center at Saint Joseph's | Phoenix | Arizona |
United States | FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst | North Carolina |
United States | Oregon Health and Science University | Portland | Oregon |
United States | Providence Portland Medical Center | Portland | Oregon |
United States | Providence Saint Vincent Medical Center | Portland | Oregon |
United States | Illinois CancerCare-Princeton | Princeton | Illinois |
United States | Duke Raleigh Hospital | Raleigh | North Carolina |
United States | Marshfield Medical Center-Rice Lake | Rice Lake | Wisconsin |
United States | UT Southwestern Clinical Center at Richardson/Plano | Richardson | Texas |
United States | VCU Massey Cancer Center at Stony Point | Richmond | Virginia |
United States | Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia |
United States | Kaiser Permanente-Riverside | Riverside | California |
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
United States | Ascension Saint Mary's Hospital | Saginaw | Michigan |
United States | Oncology Hematology Associates of Saginaw Valley PC | Saginaw | Michigan |
United States | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph | Michigan |
United States | Missouri Baptist Medical Center | Saint Louis | Missouri |
United States | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Minnesota |
United States | Regions Hospital | Saint Paul | Minnesota |
United States | United Hospital | Saint Paul | Minnesota |
United States | Sainte Genevieve County Memorial Hospital | Sainte Genevieve | Missouri |
United States | Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah |
United States | University of Texas Health Science Center at San Antonio | San Antonio | Texas |
United States | Kaiser Permanente-San Diego Zion | San Diego | California |
United States | Kaiser Permanente-San Marcos | San Marcos | California |
United States | Memorial Medical Center | Springfield | Illinois |
United States | Southern Illinois University School of Medicine | Springfield | Illinois |
United States | Springfield Clinic | Springfield | Illinois |
United States | Marshfield Medical Center-River Region at Stevens Point | Stevens Point | Wisconsin |
United States | Missouri Baptist Sullivan Hospital | Sullivan | Missouri |
United States | BJC Outpatient Center at Sunset Hills | Sunset Hills | Missouri |
United States | Ascension Saint Joseph Hospital | Tawas City | Michigan |
United States | Cotton O'Neil Cancer Center / Stormont Vail Health | Topeka | Kansas |
United States | Munson Medical Center | Traverse City | Michigan |
United States | Upper Valley Medical Center | Troy | Ohio |
United States | Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa | Oklahoma |
United States | Saint Luke's Cancer Institute - Twin Falls | Twin Falls | Idaho |
United States | Carle Cancer Center | Urbana | Illinois |
United States | Epic Care Cyberknife Center | Walnut Creek | California |
United States | Northwestern Medicine Cancer Center Warrenville | Warrenville | Illinois |
United States | Illinois CancerCare - Washington | Washington | Illinois |
United States | Saint Mary's Oncology/Hematology Associates of West Branch | West Branch | Michigan |
United States | Marshfield Medical Center - Weston | Weston | Wisconsin |
United States | Kaiser Permanente-Woodland Hills | Woodland Hills | California |
United States | University of Michigan Health - West | Wyoming | Michigan |
United States | Huron Gastroenterology PC | Ypsilanti | Michigan |
United States | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti | Michigan |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression free survival | A proportional hazards model will be used to evaluate the experimental arm compared to the control arm, adjusted for the stratification factors as covariates in the model. A one-sided p-value =< 0.05 will indicate statistical significance. Participants last known to be alive and progression free are censored at date of last contact. | From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years | |
Secondary | Overall survival | Will be estimated by the Kaplan-Meier method, and a stratified log-rank test will be used to compare the treatment arms. Participants last known to be alive are censored at date of last contact. | From date of registration to date of death due to any cause, assessed up to 5 years | |
Secondary | Objective response rate | Will be estimated to within +/- 11% (95% confidence interval). | Up to 5 years | |
Secondary | Incidence of adverse events | Will be estimated to within +/- 11% (95% confidence interval). Will utilize the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 for toxicity and serious adverse event reporting. | Day 1 of each cycle |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05863351 -
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
|
Phase 3 | |
Recruiting |
NCT06049576 -
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
|
Phase 1 | |
Active, not recruiting |
NCT04467021 -
Cancer and Blood Pressure Management, CARISMA Study
|
N/A | |
Withdrawn |
NCT04603365 -
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
|
Phase 2 | |
Recruiting |
NCT05112627 -
Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy
|
||
Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
Active, not recruiting |
NCT05122546 -
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06391099 -
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer
|
N/A | |
Active, not recruiting |
NCT04904302 -
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03473730 -
Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
|
Early Phase 1 | |
Active, not recruiting |
NCT03541902 -
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03829111 -
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
|
Phase 1 | |
Recruiting |
NCT03866382 -
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
|
Phase 2 | |
Recruiting |
NCT04510597 -
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
|
Phase 3 | |
Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04693377 -
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
|
N/A | |
Recruiting |
NCT06265285 -
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
|
Phase 2 | |
Active, not recruiting |
NCT03793166 -
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
|
Phase 3 | |
Recruiting |
NCT05327686 -
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
|
Phase 2 | |
Active, not recruiting |
NCT02419495 -
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
|
Phase 1 |